 Kazia Therapeutics Ltd ASX:KZA, NASDAQ:KZIA has received the nod from two research houses, with the Maxim Group LLC initiating coverage with a buy recommendation and Edison increasing its valuation to A2.83 from A2.68 per basic share. The Maxim Group has also put a 12-month target price of US18 per American Depository Share ADS, which is also listed on NASDAQ. 